Arkolith/Insider Trading/TRDA/Form 4

Wentworth Kory James

Chief Financial OfficerEntrada Therapeutics, Inc. (TRDA) · full profile →Form 4 · filed Mar 4, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 3, 2025Tax withholding(F)5K$11.68$58K111K
Mar 1, 2025Grant(A)42K—$0116K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 1, 2025Grant(A)63K—$063K

Transaction Codes

F
Shares withheld for taxes
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001689375-25-000014) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML